Hypertension [dsyn]
Heterogeneous [qlco]
Disease [dsyn]
reflected [menp]
Marked [qlco]
Variability [cnce]
Response [orga]
Administer [ftcn]
Antihypertensive therapy [topp]
Several [qnco]
Theoretical [idcn]
Benefits [qnco]
Enhanced [acty]
Efficacy [qlco]
Improved [qlco]
TOLERABILITY [resa]
Increased [qnco]
Compliance [qnco]
Cases [ftcn]
Biochemical [ftcn]
variables [qlco]
Associated [qlco]
Increased [qnco]
CARDIOVASCULAR [bdsy]
Risk [qlco]
Improvement [cnce]
Lipid [lipd]
Profile [lbpr]
Doxazosin [orch, phsu]
Several [qnco]
Favorable [qlco]
properties [qlco]
Agent [chvf]
Mechanism [ftcn]
Action [ftcn]
Four [qnco]
Main [qlco]
Group [idcn]
Anti-Hypertensive Drugs [phsu]
Case [ftcn]
Enhanced [acty]
Efficacy [qlco]
Beer [food]
Observed [ftcn]
Blockade [ftcn]
Added [ftcn]
Drug [phsu]
Class [inpr]
Synergistic [qlco]
Effect [qlco]
Seen [qlco]
Administered [ftcn]
Calcium channel blocker [phsu]
Angiotensin-converting enzyme inhibitor [phsu]
Induce [ftcn]
Regression [patf]
Left Ventricular Hypertrophy [dsyn]
Enhanced [acty]
effects [qlco]
Multiple therapy [topp]
Not [ftcn]
exert [orgf]
effects [qlco]
Lipids [lipd]
Limited [ftcn]
Data [idcn]
Suggest [idcn]
Able [orga]
Reverse [idcn]
Lipid [lipd]
effects [qlco]
Diuretics [phsu]
Beta-Blockers [phsu]
exert [orgf]
Neutral [qlco]
effects [qlco]
glucose homeostasis [phsf]
Further [spco]
studies [lbpr]
Needed [qlco]
To [qlco]
adverse effects [ftcn]
Beta-Blockers [phsu]
Diuretics [phsu]
glucose homeostasis [phsf]
GIVEN [cnce]
Anti-Hypertensive Drugs [phsu]
Well [qlco]
Patient Compliance [inbe]
Current [tmco]
Data [idcn]
FAVOR [orch, phsu, vita]
MSE [gngm]
Additional [ftcn]
Component [mnob]
Antihypertensive therapy [topp]
Further [spco]
studies [lbpr]
Needed [qlco]
To [qlco]
Address [inpr]
Metabolic [ftcn]
End [spco]
Organ [bpoc]
effects [qlco]
Treatment Regimen [topp]
